Boryung Corporation
Financials
Valuation Metrics
Boryung Corporation's Market Cap is ₩7163B. At end of 2025 it was ₩7729B. Ranked #357 of 2,436 in KR market (top 15%), #246 of 787 on KOSPI (top 31%), #40 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 17%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 716.32B KRW | KR#357/2,436 Sec#40/234 |
| Revenue | 1.03T KRW | KR#393/2,436 Sec#13/234 |
| Net Income | 105.39B KRW | KR#209/2,436 Sec#12/234 |
| Total Assets | 1.40T KRW | KR#381/2,436 Sec#17/234 |
| Net Assets | 873.71B KRW | KR#313/2,436 Sec#20/234 |
| Employees | 1,646 | KR#166/2,436 Sec#10/234 |
| Value | ||
| P/E | 6.80x | KR#453/2,436 Sec#19/234 |
| P/B | 0.82x | KR#1,314/2,436 Sec#79/234 |
| PEG | 0.00x | KR#7/2,436 Sec#1/234 |
| P/S | 0.69x | KR#1,147/2,436 Sec#56/234 |
| EV/EBITDA | 8.88x | KR#524/2,436 Sec#23/234 |
| FCF Yield | 15.49% | KR#437/2,436 Sec#10/234 |
| Profitability | ||
| ROE | 12.06% | KR#374/2,436 Sec#24/234 |
| ROA | 7.52% | KR#377/2,436 Sec#30/234 |
| Op. Margin | 7.20% | KR#684/2,436 Sec#59/234 |
| Revenue Growth | 6.15% | KR#1,114/2,436 Sec#101/234 |
| Earnings Growth | 11762.37% | KR#7/2,436 Sec#1/234 |
| Financial Health | ||
| Debt Ratio | 60.46% | KR#206/2,436 Sec#29/234 |
| Total Debt | 199.61B KRW | KR#489/2,436 Sec#26/234 |
| FCF | 110.94B KRW | KR#183/2,436 Sec#10/234 |
| Cash | 256.18B KRW | KR#235/2,436 Sec#7/234 |
| Current Ratio | 2.61x | KR#710/2,436 Sec#89/234 |
| Net Debt/EBITDA | -0.76x | KR#523/2,436 Sec#31/234 |
| Dividend | ||
| Div. Yield | 1.97% | KR#901/2,436 Sec#45/234 |
| Div. Growth | 60.00% | KR#194/2,436 Sec#6/234 |
| Performance | ||
| 1Y Return | 1.09% | KR#690/2,436 Sec#53/234 |
| 1M Return | -1.18% | KR#1,016/2,436 Sec#97/234 |
| From 52W High | -22.69% | KR#221/2,436 Sec#12/234 |
| 1Y MDD | -29.12% | KR#184/2,436 Sec#10/234 |
| Trading | ||
| Volume | 67,917 shares | KR#1,166/2,436 Sec#113/234 |
| Foreign Own. | 6.11% | KR#705/2,436 Sec#69/234 |
| Per Share | ||
| EPS | 1,229 KRW | KR#551/2,436 Sec#39/234 |
| BPS | 10,342 KRW | KR#921/2,436 Sec#65/234 |
Company Info
Boryung, established in 1963 and listed on the securities market in 1988, operates in pharmaceutical manufacturing and sales. The company is expanding its market share in chronic metabolic diseases and oncology with its new drug Kanarb in the professional pharmaceutical sector, achieving results across diverse business divisions. Boryung strives to become a leading healthcare company with high profitability and stable cash generation by maximizing proprietary product capabilities and expanding essential medicine manufacturing infrastructure. Boryung is headquartered in Jongno-gu, Seoul.